查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1984889

全球末期肾功能衰竭市场：按治疗方法和地区划分－市场规模、产业趋势、主要企业、技术、机会分析和未来预测（2026-2035 年）

Global End Stage Renal Disease Market: By Treatment, Region-Market Size, Industry Dynamics, Companies, Technology, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 210 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球末期肾功能衰竭（ESRD）市场正经历显着且持续的成长，反映出全球肾臟相关健康问题日益加重的负担。 2025年，该市场规模约为1,526.4亿美元，预计到2035年将大幅成长至5,738.6亿美元。这意味着在2026年至2035年的预测期内，该市场将以14.16%的复合年增长率成长，凸显了ESRD市场的快速发展和扩张。

多种因素推动了这一强劲成长。其中一个主要因素是糖尿病和高血压等慢性疾病的盛行率不断上升，而这些疾病正是末期肾病变（ESRD）的主要病因。随着这些疾病在全球的增加，需要透析或其他肾臟替代疗法的患者人数持续成长。此外，人口结构的变化，特别是许多地区的人口老化，也增加了对ESRD治疗的需求，因为老年人更容易发生肾衰竭及其併发症。

显着的市场趋势

在全球末期肾功能衰竭（ESRD）市场，费森尤斯医疗照护（FME）和达维塔（DaVita）是塑造产业格局的主要企业。这两家公司实际上形成了双寡占格局，各自凭藉着独特的经营模式和策略倡议，在这个高度专业化的医疗保健领域确立并保持着主导地位。

费森尤斯医疗照护采用垂直整合的经营模式，自行生产透析机和诊所使用的设备。这种整合模式赋予费森尤斯显着优势，使其免受供应链中断的影响，并确保其营运所需的医疗设备供应稳定可靠。

同时，达维塔选择专注于服务提供而非设备製造。其优势在于营运透析诊所和患者照护管理，这使其能够集中资源提供高品质服务，而非生产设备。达维塔的成长策略以积极的国际併购为特征，从而能够迅速扩张至新市场。事实证明，这种策略在拉丁美洲尤其有效，该公司已在巴西和哥伦比亚等国建立了强大的市场地位。

主要成长要素

末期肾功能衰竭（ESRD）市场成长的主要驱动因素是全球第2型糖尿病和高血压盛行率的持续上升。这两种慢性疾病是导致肾臟损伤并最终发展为ESRD的主要原因。尤其值得关注的是，糖尿病患者人数的激增引起了医疗专业人员和研究人员的极大关注。根据国际糖尿病联盟（IDF）的最新估计，目前全球约有5.37亿成年人患有糖尿病。预计到2030年，这一数字将大幅增长至约6.43亿，反映出这种代谢性疾病对全球健康带来的严峻挑战。

新机会的趋势

穿戴式人工肾臟的研发和低维护成本透析机的进步，代表着充满希望的新兴机会，并有望在未来几年显着推动市场成长。特别是穿戴式人工肾，与传统透析方法相比，能够为患者提供更大的活动自由度，从而彻底改变透析治疗方式。这些小巧便携的设备能够持续过滤血液中的代谢废物和多余液体，使患者能够在日常生活中接受治疗，而无需被笨重的固定式机器束缚。这项创新不仅有望提高病患的生活质量，还能减少就医次数，降低相关医疗成本。

优化障碍

透析和移植都需要长期护理，这不仅会给患者带来沉重的负担，也会给医疗系统带来巨大压力。透析是维持生命所必需的，但它需要每週多次持续治疗，而且在许多情况下，如果移植不可行，治疗就必须持续终生。除了这些反覆的治疗外，相关的医疗监测、药物以及潜在的併发症也会随着时间的推移累积成巨额费用。对于许多患者，特别是那些没有全面医疗保险或居住在医疗津贴有限的地区的患者来说，这些费用可能成为难以承受的负担，使他们难以获得治疗和维持持续的护理。

目录

第一章执行摘要：全球末期肾功能衰竭市场

第二章：调查方法与研究框架

  • 研究目标
  • 产品概述
  • 市场区隔
  • 定性研究
    • 一手和二手资讯
  • 量化研究
    • 一手和二手资讯
  • 初步调查受访者组成：依地区划分
  • 本研究的前提
  • 市场规模估算
  • 数据检验

第三章：全球末期肾功能衰竭市场概览

  • 产业价值链分析
    • 原物料供应商
    • 製造商
    • 销售代理
    • 最终用户
  • 产业展望
    • 2023年肾臟疾病调查中的九项突破性进展
    • 末期肾功能衰竭治疗药物研发管线概述
    • 末期肾功能衰竭的年度治疗费用
    • 末期肾功能衰竭的流行病学
    • 案例研究分析
  • PESTLE分析
  • 波特五力分析
    • 供应商的议价能力
    • 买方的议价能力
    • 替代品的威胁
    • 新进入者的威胁
    • 竞争强度
  • 市场成长及前景
    • 市场收入估算与预测（2020-2035 年）
    • 价格趋势分析

第四章：全球末期肾功能衰竭市场分析

  • 竞争对手仪錶板
    • 市场集中度
    • 企业市场占有率分析（2025 年）
    • 竞争格局分析与基准测试

第五章：全球末期肾功能衰竭市场分析

  • 市场动态和趋势
    • 成长要素
    • 抑制因子
    • 机会
    • 主要趋势
  • 市场规模及预测（2020-2035）
    • 透过治疗方法
    • 依产品类型
    • 按年龄组
    • 最终用户
    • 按地区

第六章：北美市场分析

第七章：欧洲市场分析

第八章：亚太市场分析

第九章：中东和非洲市场分析

第十章：南美市场分析

第十一章：公司简介

  • Cantel Medical
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • AngioDynamics, Inc.
  • Becton Dickinson and Company
  • DaVita Inc.
  • US Renal Care, Inc.
  • JMS Co. Ltd.
  • Medtronic Plc
  • Nikkiso Co., Ltd.
  • Fresenius Medical Care AG &Co. KGaA
  • Nipro Corporation
  • Teleflex Incorporated
  • Toray Industries Inc.
  • 其他主要企业

第十二章附录

简介目录
Product Code: AA02261697

The global End Stage Renal Disease (ESRD) market is experiencing significant and sustained growth, reflecting the increasing burden of kidney-related health issues worldwide. In 2025, the market was valued at approximately USD 152.64 billion, and projections indicate a remarkable expansion to USD 573.86 billion by 2035. This represents a compound annual growth rate (CAGR) of 14.16% over the forecast period from 2026 to 2035, underscoring the rapid pace at which the ESRD market is evolving and expanding.

Several factors are driving this robust growth. One of the primary contributors is the rising prevalence of chronic conditions such as diabetes and hypertension, which are the leading causes of ESRD. As these diseases become more common globally, the number of patients requiring dialysis and other renal replacement therapies continues to grow. Additionally, demographic shifts, particularly aging populations in many regions, are increasing the demand for ESRD treatments, as older individuals are more susceptible to kidney failure and related complications.

Noteworthy Market Developments

In the global end stage renal disease (ESRD) market, two companies stand out as the dominant players shaping the industry landscape: Fresenius Medical Care (FME) and DaVita. These two entities effectively form a duopoly, each with distinct business models and strategic approaches that have allowed them to secure and maintain leading positions in this highly specialized healthcare sector.

Fresenius Medical Care operates with a vertically integrated business model, which means that they manufacture the dialysis machines and equipment used in its own clinics. This integration provides Fresenius with a significant advantage by shielding the company from disruptions in the supply chain, ensuring a steady and reliable flow of essential medical devices for its operations.

On the other hand, DaVita has chosen to focus exclusively on service delivery rather than manufacturing. Their core strength lies in operating dialysis clinics and managing patient care, which allows them to concentrate resources on providing high-quality services rather than device production. DaVita's growth strategy is characterized by aggressive international mergers and acquisitions (M&A), enabling rapid expansion into new markets. This approach has proven particularly effective in regions such as Latin America, where they have established a strong presence in countries like Brazil and Colombia.

Core Growth Drivers

The primary factor driving the growth of the end stage renal disease (ESRD) market is the steadily increasing prevalence of Type 2 Diabetes Mellitus and Hypertension worldwide. These two chronic conditions are major contributors to kidney damage, ultimately leading to ESRD. The alarming rise in the number of individuals affected by diabetes, in particular, has been a significant concern for healthcare professionals and researchers alike. Recent estimates from the International Diabetes Federation (IDF) reveal that around 537 million adults are currently living with diabetes globally. This number is expected to surge dramatically, reaching approximately 643 million by the year 2030, reflecting the ongoing global health challenge posed by this metabolic disorder.

Emerging Opportunity Trends

The development of wearable artificial kidneys and advancements in low-maintenance dialysis machines represent promising emerging opportunities that could significantly drive market growth in the coming years. Wearable artificial kidneys, in particular, are poised to revolutionize the treatment landscape by offering patients greater mobility and freedom compared to traditional dialysis methods. These compact, portable devices aim to continuously perform the essential functions of filtering waste and excess fluids from the blood, allowing patients to receive treatment throughout their daily activities without being tethered to bulky, stationary machines. This innovation not only has the potential to improve patients' quality of life but also to reduce the frequency of hospital visits and associated healthcare costs.

Barriers to Optimization

The long-term care required for both dialysis and transplantation involves substantial financial costs, which can place a heavy burden on patients as well as healthcare systems. Dialysis, while life-sustaining, demands ongoing treatments multiple times a week, often for the remainder of a patient's life if a transplant is not available. These repeated sessions, along with the associated medical monitoring, medications, and potential complications, accumulate into significant expenses over time. For many patients, especially those without comprehensive insurance coverage or in regions with limited healthcare funding, the cost can be prohibitive, leading to challenges in accessing or maintaining consistent treatment.

Detailed Market Segmentation

Based on Treatment, dialysis has firmly established itself as the most widely sought-after treatment option for patients with end-stage organ failure, commanding a dominant market share of 81.23%. This overwhelming preference for dialysis stems from its critical role as a life-sustaining therapy for individuals whose organ function has deteriorated to the point where it can no longer support their basic physiological needs. Dialysis effectively performs the essential functions of filtering and purifying the blood, thereby compensating for the loss of kidney function and prolonging patients' lives.

Segment Breakdown

  • By Treatment Type
    • Dialysis
  • Hemodialysis
  • In-center Hemodialysis
  • Home Hemodialysis
  • Peritoneal Dialysis
  • Continuous Ambulatory Peritoneal Dialysis (CAPD)
  • Automated Peritoneal Dialysis (APD)
    • Kidney Transplantation
  • Living Donor Transplant
  • Deceased Donor Transplant
    • Conservative Management
  • By Product Type
    • Equipment
  • Hemodialysis Machines
  • Peritoneal Dialysis Machines
  • Water Treatment Systems
  • Dialysis Monitoring Systems
    • Consumables
  • Dialyzers
  • Bloodline Sets
  • Dialysate Solutions
  • Catheters
  • AV Fistula Needles
  • Tubing Systems
    • Drugs
  • Erythropoiesis Stimulating Agents
  • Phosphate Binders
  • Vitamin D Analogs
  • Iron Supplements
  • Others
    • Services
  • Dialysis Services
  • Maintenance Services
  • Telehealth Monitoring
  • By Age Group
    • Pediatric
    • Adult
    • Geriatric
  • By End User
    • Dialysis Centers
    • Hospitals
    • Specialty Clinics
    • Home Care Settings
  • By Region
  • North America
    • The U.S.
    • Canada
    • Mexico
  • Europe
    • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
    • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Australia & New Zealand
    • ASEAN
  • Indonesia
  • Malaysia
  • Thailand
  • Singapore
  • Rest of ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • South Africa
    • Rest of MEA
  • South America
    • Argentina
    • Brazil
    • Rest of South America

Geography Breakdown

Asia Pacific holds a commanding position in the End Stage Renal Disorder (ESRD) market, capturing nearly 37% of the global market share. This dominance can be attributed to several key factors that are unique to the region. One of the primary drivers is the rapidly growing patient population, which is increasing the demand for renal care and related treatments. The region's healthcare systems are also actively responding to this growing burden through aggressive public health interventions aimed at improving diagnosis, management, and treatment outcomes for ESRD patients.

The Asia Pacific region faces a complex and dual challenge in managing the ESRD burden. On one hand, developed countries such as Japan are grappling with aging populations, which naturally lead to higher incidences of chronic conditions like renal failure. On the other hand, emerging economies within the region are experiencing a significant rise in diabetic nephropathy, a complication of diabetes that often progresses to ESRD. This rising tide of diabetes-driven kidney disease is putting additional strain on healthcare resources and necessitating tailored strategies to address the unique needs of these diverse populations.

Leading Market Participants

  • Cantel Medical
  • Asahi Kasei Medical Co., Ltd.
  • B. Braun Melsungen AG
  • Baxter International, Inc.
  • AngioDynamics, Inc.
  • Becton Dickinson and Company
  • DaVita Inc.
  • U.S. Renal Care, Inc.
  • JMS Co. Ltd.
  • Medtronic Plc
  • Nikkiso Co., Ltd.
  • Fresenius Medical Care AG & Co. KGaA
  • Nipro Corporation
  • Teleflex Incorporated
  • Toray Industries Inc.
  • Other Prominent Players

Table of Content

Chapter 1. Executive Summary: Global End Stage Renal Disease Market

Chapter 2. Research Methodology & Research Framework

  • 2.1. Research Objective
  • 2.2. Product Overview
  • 2.3. Market Segmentation
  • 2.4. Qualitative Research
    • 2.4.1. Primary & Secondary Sources
  • 2.5. Quantitative Research
    • 2.5.1. Primary & Secondary Sources
  • 2.6. Breakdown of Primary Research Respondents, By Region
  • 2.7. Assumption for Study
  • 2.8. Market Size Estimation
  • 2.9. Data Triangulation

Chapter 3. Global End Stage Renal Disease Market Overview

  • 3.1. Industry Value Chain Analysis
    • 3.1.1. Raw Material Suppliers
    • 3.1.2. Manufacturers
    • 3.1.3. Distributors
    • 3.1.4. End User
  • 3.2. Industry Outlook
    • 3.2.1. Nine Kidney Disease Research Breakthroughs from 2023
    • 3.2.2. Overview of End Stage Renal Disease Drugs Pipeline
    • 3.2.3. Annual Treatment Cost of End Stage Renal Disease
    • 3.2.4. Epidemiology of End Stage Renal Disease
    • 3.2.5. Case Study Analysis
      • 3.2.5.1. Chronic Kidney Disease and the Global Public Health Agenda: An International Consensus
      • 3.2.5.2. Management of Chronic Kidney Disease: The Current Novel and Forgotten Therapies
  • 3.3. PESTLE Analysis
  • 3.4. Porter's Five Forces Analysis
    • 3.4.1. Bargaining Power of Suppliers
    • 3.4.2. Bargaining Power of Buyers
    • 3.4.3. Threat of Substitutes
    • 3.4.4. Threat of New Entrants
    • 3.4.5. Degree of Competition
  • 3.5. Market Growth and Outlook
    • 3.5.1. Market Revenue Estimates and Forecast (US$ Mn), 2020-2035
    • 3.5.2. Price Trend Analysis

Chapter 4. Global End Stage Renal Disease Market Analysis

  • 4.1. Competition Dashboard
    • 4.1.1. Market Concentration Rate
    • 4.1.2. Company Market Share Analysis (Value %), 2025
    • 4.1.3. Competitor Mapping & Benchmarking

Chapter 5. Global End Stage Renal Disease Market Analysis

  • 5.1. Market Dynamics and Trends
    • 5.1.1. Growth Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Key Trends
  • 5.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 5.2.1. By Treatment Type
      • 5.2.1.1. Key Insights
        • 5.2.1.1.1. Dialysis
          • 5.2.1.1.1.1. Hemodialysis
            • 5.2.1.1.1.1.1. In-center Hemodialysis
            • 5.2.1.1.1.1.2. Home Hemodialysis
          • 5.2.1.1.1.2. Peritoneal Dialysis
          • 5.2.1.1.1.3. Continuous Ambulatory Peritoneal Dialysis (CAPD)
          • 5.2.1.1.1.4. Automated Peritoneal Dialysis (APD)
        • 5.2.1.1.2. Kidney Transplantation
          • 5.2.1.1.2.1. Living Donor Transplant
          • 5.2.1.1.2.2. Deceased Donor Transplant
        • 5.2.1.1.3. Conservative Management
    • 5.2.2. By Product Type
      • 5.2.2.1. Key Insights
        • 5.2.2.1.1. Equipment
          • 5.2.2.1.1.1. Hemodialysis Machines
          • 5.2.2.1.1.2. Peritoneal Dialysis Machines
          • 5.2.2.1.1.3. Water Treatment Systems
          • 5.2.2.1.1.4. Dialysis Monitoring Systems
        • 5.2.2.1.2. Consumables
          • 5.2.2.1.2.1. Dialyzers
          • 5.2.2.1.2.2. Bloodline Sets
          • 5.2.2.1.2.3. Dialysate Solutions
          • 5.2.2.1.2.4. Catheters
          • 5.2.2.1.2.5. AV Fistula Needles
          • 5.2.2.1.2.6. Tubing Systems
        • 5.2.2.1.3. Drugs
          • 5.2.2.1.3.1. Erythropoiesis Stimulating Agents
          • 5.2.2.1.3.2. Phosphate Binders
          • 5.2.2.1.3.3. Vitamin D Analogs
          • 5.2.2.1.3.4. Iron Supplements
          • 5.2.2.1.3.5. Others
        • 5.2.2.1.4. Services
          • 5.2.2.1.4.1. Dialysis Services
          • 5.2.2.1.4.2. Maintenance Services
          • 5.2.2.1.4.3. Telehealth Monitoring
    • 5.2.3. By Age Group
      • 5.2.3.1. Key Insights
        • 5.2.3.1.1. Pediatric
        • 5.2.3.1.2. Adult
        • 5.2.3.1.3. Geriatric
    • 5.2.4. By End User
      • 5.2.4.1. Key Insights
        • 5.2.4.1.1. Dialysis Centers
        • 5.2.4.1.2. Hospitals
        • 5.2.4.1.3. Specialty Clinics
        • 5.2.4.1.4. Home Care Settings
    • 5.2.5. By Region
      • 5.2.5.1. Key Insights
        • 5.2.5.1.1. North America
          • 5.2.5.1.1.1. The U.S.
          • 5.2.5.1.1.2. Canada
          • 5.2.5.1.1.3. Mexico
        • 5.2.5.1.2. Europe
          • 5.2.5.1.2.1. Western Europe
            • 5.2.5.1.2.1.1. The UK
            • 5.2.5.1.2.1.2. Germany
            • 5.2.5.1.2.1.3. France
            • 5.2.5.1.2.1.4. Italy
            • 5.2.5.1.2.1.5. Spain
            • 5.2.5.1.2.1.6. Rest of Western Europe
          • 5.2.5.1.2.2. Eastern Europe
            • 5.2.5.1.2.2.1. Poland
            • 5.2.5.1.2.2.2. Russia
            • 5.2.5.1.2.2.3. Rest of Eastern Europe
        • 5.2.5.1.3. Asia Pacific
          • 5.2.5.1.3.1. China
          • 5.2.5.1.3.2. India
          • 5.2.5.1.3.3. Japan
          • 5.2.5.1.3.4. South Korea
          • 5.2.5.1.3.5. Australia & New Zealand
          • 5.2.5.1.3.6. ASEAN
            • 5.2.5.1.3.6.1. Indonesia
            • 5.2.5.1.3.6.2. Malaysia
            • 5.2.5.1.3.6.3. Thailand
            • 5.2.5.1.3.6.4. Singapore
            • 5.2.5.1.3.6.5. Rest of ASEAN
          • 5.2.5.1.3.7. Rest of Asia Pacific
        • 5.2.5.1.4. Middle East & Africa
          • 5.2.5.1.4.1. UAE
          • 5.2.5.1.4.2. Saudi Arabia
          • 5.2.5.1.4.3. South Africa
          • 5.2.5.1.4.4. Rest of MEA
        • 5.2.5.1.5. South America
          • 5.2.5.1.5.1. Argentina
          • 5.2.5.1.5.2. Brazil
          • 5.2.5.1.5.3. Rest of South America

Chapter 6. North America Market Analysis

  • 6.1. Market Dynamics and Trends
    • 6.1.1. Growth Drivers
    • 6.1.2. Restraints
    • 6.1.3. Opportunity
    • 6.1.4. Key Trends
  • 6.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 6.2.1. Key Insights
      • 6.2.1.1. By Treatment Type
      • 6.2.1.2. By Product Type
      • 6.2.1.3. By Age Group
      • 6.2.1.4. By End User
      • 6.2.1.5. By Country

Chapter 7. Europe Market Analysis

  • 7.1. Market Dynamics and Trends
    • 7.1.1. Growth Drivers
    • 7.1.2. Restraints
    • 7.1.3. Opportunity
    • 7.1.4. Key Trends
  • 7.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 7.2.1. Key Insights
      • 7.2.1.1. By Treatment Type
      • 7.2.1.2. By Product Type
      • 7.2.1.3. By Age Group
      • 7.2.1.4. By End User
      • 7.2.1.5. By Country

Chapter 8. Asia Pacific Market Analysis

  • 8.1. Market Dynamics and Trends
    • 8.1.1. Growth Drivers
    • 8.1.2. Restraints
    • 8.1.3. Opportunity
    • 8.1.4. Key Trends
  • 8.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 8.2.1. Key Insights
      • 8.2.1.1. By Treatment Type
      • 8.2.1.2. By Product Type
      • 8.2.1.3. By Age Group
      • 8.2.1.4. By End User
      • 8.2.1.5. By Country

Chapter 9. Middle East & Africa Market Analysis

  • 9.1. Market Dynamics and Trends
    • 9.1.1. Growth Drivers
    • 9.1.2. Restraints
    • 9.1.3. Opportunity
    • 9.1.4. Key Trends
  • 9.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 9.2.1. Key Insights
      • 9.2.1.1. By Treatment Type
      • 9.2.1.2. By Product Type
      • 9.2.1.3. By Age Group
      • 9.2.1.4. By End User
      • 9.2.1.5. By Country

Chapter 10. South America Market Analysis

  • 10.1. Market Dynamics and Trends
    • 10.1.1. Growth Drivers
    • 10.1.2. Restraints
    • 10.1.3. Opportunity
    • 10.1.4. Key Trends
  • 10.2. Market Size and Forecast, 2020-2035 (US$ Mn)
    • 10.2.1. Key Insights
      • 10.2.1.1. By Treatment Type
      • 10.2.1.2. By Product Type
      • 10.2.1.3. By Age Group
      • 10.2.1.4. By End User
      • 10.2.1.5. By Country

Chapter 11. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 11.1. Cantel Medical
  • 11.2. Asahi Kasei Medical Co., Ltd.
  • 11.3. B. Braun Melsungen AG
  • 11.4. Baxter International, Inc.
  • 11.5. AngioDynamics, Inc.
  • 11.6. Becton Dickinson and Company
  • 11.7. DaVita Inc.
  • 11.8. U.S. Renal Care, Inc.
  • 11.9. JMS Co. Ltd.
  • 11.10. Medtronic Plc
  • 11.11. Nikkiso Co., Ltd.
  • 11.12. Fresenius Medical Care AG & Co. KGaA
  • 11.13. Nipro Corporation
  • 11.14. Teleflex Incorporated
  • 11.15. Toray Industries Inc.
  • 11.16. Other Prominent Players

Chapter 12. Annexure

  • 12.1. List of Secondary Sources
  • 12.2. Key Country Markets- Macro Economic Outlook/Indicators